Modifying effect of AD pathology in the association between CSF synaptic biomarkers and brain function and structure in preclinical Alzheimer

MLA

Marta Milà‐Alomà, et al. “Modifying Effect of AD Pathology in the Association between CSF Synaptic Biomarkers and Brain Function and Structure in Preclinical Alzheimer.” Alzheimer’s & Dementia, vol. 18, Dec. 2022. EBSCOhost, https://doi.org/10.1002/alz.065600.

APA

Marta Milà‐Alomà, Raffaele Cacciaglia, Mahnaz Shekari, Grégory Operto, Ann Brinkmalm, Hlin Kvartsberg, Nicholas J. Ashton, Gwendlyn Kollmorgen, Norbert Wild, Ivonne Suridjan, Henrik Zetterberg, Kaj Blennow, Jose Luis Molinuevo, Juan Domingo Gispert, & Marc Suárez‐Calvet. (2022). Modifying effect of AD pathology in the association between CSF synaptic biomarkers and brain function and structure in preclinical Alzheimer. Alzheimer’s & Dementia, 18. https://doi.org/10.1002/alz.065600

Chicago

Marta Milà‐Alomà, Raffaele Cacciaglia, Mahnaz Shekari, Grégory Operto, Ann Brinkmalm, Hlin Kvartsberg, Nicholas J. Ashton, et al. 2022. “Modifying Effect of AD Pathology in the Association between CSF Synaptic Biomarkers and Brain Function and Structure in Preclinical Alzheimer.” Alzheimer’s & Dementia 18 (December). doi:10.1002/alz.065600.